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A B S T R A C T
The selection of antipsychotics as medications used primarily for treating schizophrenia and disorders similar to
schizophrenia is an important aspect of the treatment of forensic patients. This study examines the effect of antipsychotics
selection (typical or atipycal) on the level of aggressiveness, side effects and the hospitalisation length. The research is
conducted on 98 psychiatric patients diagnosed with schizophrenia or similar disorders (F 20-F 29) in two forensic psy-
chiatric institutions. The patients committed aggressive criminal offence in state of insanity. The patients are currently
treated in inpatient psychiatric institutions. The research was conducted by using the Aggressiveness Questionnaire
(AG-87), the Simpson-Angus Scale for the assessment of extrapyramidal side effects, the Barnes Akathisia Rating Scale
for the assesment of akathisia and the Abnormal Involuntary Movement Scale. The results show no significant differ-
ence between the groups of patients treated with typical and atypical antipsychotics in all the variables.
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Introduction
There are many dilemmas regarding the issue of ag-
gressiveness in mental patients, especially in patients
suffering from schizophrenia. Some authors hold that
comorbidity with personality disorder and/or substance
abuse elevates the level of aggressiveness in schizophre-
nic patients1–8. The regulation and prediction of aggres-
siveness is extremely important factor in treating mental
patients who committed criminal offence, during their
stay in the institution as well as after discharge.
In general, the medication that affects the basic ill-
ness by reducing the psychopathological manifestation
should also reduce the level of aggressiveness9,10. In or-
der to achieve this, we need to prescribe the medication
that corresponds to recommended algorithm11, has the
minimum of undesirable effects and works the best for a
patient. Patient cooperation joined with optimum medi-
cation efficiency is the best prognostic factor not only in
relapse prevention, but also in prevention of aggressive
offence12.
Antipsychotics are the first choice in the treatment of
schizophrenic patients in penal conditions too. Typical
antipsychotics, which have been in use for fifty years, af-
fect the positive symptoms of schizophrenia, but they
also cause side effects, especially the extrapyramidal
symptoms which occur in 15 to 31 percent of the cases,
even 60 percent according to some sources13. Apart from
being unpleasant, these side effects stigmatize the pa-
tient and reduce patient cooperation.
Moreover, there are some indications that akathisia is
the risk factor for aggressiveness14,15. It is not entirely
clear whether antipsychotics affect the aggressiveness
selectively and independently of their antipsychotic and
sedative effects16.
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In the last decade atypical antipsychotics are more
and more in use although the evidence on the superiority
of atypicals is mixed and it is clear that there is no »class
effect«, whereby all atypicals have superior efficacy com-
pared to typicals. Many research indicate that certain
atypical antipsychotics, especially clozapine, can reduce
persistent aggressiveness in schizophrenic patients9,17,18.
Fewer side effects could offer the possibility for a
better regulation of aggressiveness in schizophrenic pa-
tients and easier application of other therapeutic meth-
ods which improve the resocialisation of those patients.
This make atypicals possible first choice medication in
forensic shizophrenic patients.
The aim of this research was to determine whether
the selection of antipsychotics affects the level of aggres-
siveness, the manifestation of side effects and the length
of current hospitalisation in forensic patients.
Methods and Participants
The research was conducted in two forensic psychiat-
ric institutions (Popova~a and Vrap~e, Croatia). The in-
clusion criterion was that psychiatric patients committed
murder or attempted murder in state of insanity, after
which they were sent to psychiatric institution. The ex-
clusion criterion was comorbidity, i.e., the research did
not include patients with personality disorder and a his-
tory of substance abuse. At the time of research, psychi-
atric hospital in Popova~a had 210 forensic patients,
while hospital in Vrap~e had 70 patients. Ninetyeight pa-
tients (48 from Popova~a, 50 from Vrap~e) with schizo-
phrenia or psychotic disorder similar to schizophrenia (F
20 – F 29) according ICD 10 and DSM-IV met the inclu-
sion chriteria. All selected patients agreed to participate
in the research and gave their written informed consent.
Both sexes were included in unequal proportions. The
participants were divided into two groups: the patients
treated with typical antipsychotics (N=56) and the pa-
tients treated with atypical antipsychotics (N=42). The
respondents were aged 23 to 76, with a mean age of 47.3
years (M = 47.37 years, sd = 13.2).
We used the patients’ case histories to obtain de-
moraphic data, diagnosis, form of therapy and medi-
cation dosage, information on criminal offence, the level
of competence at the time of committing the offence and
information on earlier and current hospitalisations (sa-
fety measures). Questionnaires were used in further pro-
cedure.
Aggressiveness was assessed through the Aggressive-
ness Questionnaire (AG-87)19,20. The questionnaire is
based on @u`ul’s research on aggressiveness. The ques-
tionnaire specifies the level of latent aggressiveness, the
level of manifest aggressiveness and the extent of differ-
ence between them. The questionnaire contains 5 sub-
scales: verbal manifest aggressiveness (VM), physical
manifest aggressiveness (PM), indirect aggressiveness
(IN), verbal latent aggressiveness (VL) and physical la-
tent aggressiveness (PL). Participants rate themselves
on the five-point scale in terms of how often they would
behave in a described manner in particular situations.
Minimum possible score on one subscale is 15 and maxi-
mum is 75.
Extrapyramidal side effects were assessed through
the Simpson-Angus Scale (SAS)21 which consists of ten
items rating extrapyramidal side effects: leg pendulous-
ness, arm dropping, shoulder shaking, elbow rigidity,
wrist rigidity, head rotation, glabella test, salivation and
akathisia. The assessment is performed by a physician
(therapist) trained for the scale assessment. Participants
generally rate themselves on the five-point scale. The
minimum score is 10, while the maximum totals 50
points.
Akathisia was assessed by the Barnes Akathisia Rat-
ing Scale (BARS)23. The patient is observed in the sitting
and the standing position (two minutes in each position),
while engaged in an informal conversation. The scale
consists of four questions related to the characteristics of
akathisia: objective symptoms, subjective symptoms (awa-
reness of restlessness), subjective symptoms (distress re-
lated to restlessness) and global clinical assessment of
akathisia. Participants generally rate themselves on the
five-point scale. Minimum possible score is 0, maximum
score totals 20 points.
The Abnormal Involuntary Movement Scale (AIMS)23
was used to assess abnormal involuntary movements.
This is performed by a physician. The questionnaire con-
sists of 12 questions.
Statistical analysis was carried out using the SPSS,
version 11. Descriptive statistic parameters (arithmetic
mean and standard deviation) and result distribution
were calculated first, for all the variables. Internal con-
sistency reliability coefficient (Cronbach alpha) for all
the questionnaires used in the research was also calcu-
lated. Cronbach alpha was satisfactory. The independent
samples t-test was used to determine the differences be-
tween the two groups of patients (the group of patients
treated with typical antipsychotics and the group of pa-
tients taking atypical antipsychotics) in the following
variables: verbal manifest, physical manifest, verbal la-
tent and physical latent aggressiveness, as well as in the
overall level of aggressiveness, the amount of extrapy-
ramidal side effects, akathisia, abnormal involuntary
movements and the hospitalisation length.
Results
Table 1 shows the means and standard deviations, the
number of participants in each group, t-values and sig-
nificance levels (p-values) for all the variables. We have
not found any statistically significant difference between
the participants receiving typical antipsychotics therapy
and the participants receiving atypical antipsychotics
therapy, regardless of the type of aggressiveness, the
overall level of aggressiveness, the amount of extrapy-
ramidal side effects, akathisia, abnormal involuntary
movements and the hospitalisation length.
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The analysis of simultaneous application of multiple
antipsychotics (Table 2) in patients receiving typical or
atypical antipsychotics showed that prescription of mul-
tiple drugs is more common when typical antipsychotics
were prescribed. A higher percentage of patients treated
with a combination of two or more antipsychotics be-
longed to the group receiving typical neuroleptic therapy.
Discussion
The results of this research have not shown any dif-
ference between the level of aggressiveness in forensic
patients taking typical and patients taking atypical anti-
psychotics. In addition, the occurrence of side effects and
the average length of hospitalisation do not differ signifi-
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TABLE 1
DESCRIPTIVE ANALYSIS OF THE APPLIED MEASURES AND DIFFERENCES BETWEEN THE PATIENTS RECEIVING TYPICAL
ANTIPSYCHOTICS THERAPY AND THE PATIENTS RECEIVING ATYPICAL ANTIPSYCHOTICS THERAPY IN THE ASSESSED VARIABLEs
Other variables
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m 10.64 10.71 10.6




m 0.53 0.6 0.45





m 3.23 3.81 2.38





m 71.55 76.48 64.98
sd 64.58 66.56 62.64
t –0.87
p 0.387
cantly in these two groups of patients. Even though
many research indicate that atypics offer a greater possi-
bility of regulation of the positive and negative symp-
toms of schizophrenia24,25, our results are consistent with
recent studies which do not make any distinction be-
tween the effects of typical and atypical antipsychotics
regarding symptom reduction.
Both groups of antipsychotics produced the same ef-
fect on general aggressiveness and other forms of aggres-
siveness. In addition, the intensity of side effects in both
groups of patients is the same. The results of the major-
ity of current research speak in favour of the atypics pre-
cisely for milder side effects9,26.
In addition we find that polypharmacy in antipsy-
chotics therapy is reduced in patients treated with atypi-
cal antipsychotics. Although some atypicals like cloza-
pine and quetiapine have the most complex initiation
regimen of all of the antipsychotics and majority of
atypicals only come in oral form, the long term dosage re-
gime once a day for most of them seem to be more accept-
able and practical for both, the patients and doctors.
Simpler long term scheme of administration and dosage
and a better side-effect profile ascribed to atypical anti-
psychotics may help avoiding the practice of using multi-
ple medication.
This research contains certain limitations. A rela-
tively small number of participants provide a limited pos-
sibility of result generalisation. The length of hospitali-
sation for psychiatric patients is not always related to the
improvement of the clinical picture. Finally, aggressive-
ness is just one of the factors in mental state assessment,
although a very important issue regarding forensic pa-
tients.
We conclude that typical and atypical antipsychotics
proved to be comparably effective in the regulation of ag-
gressiveness in schizophrenic forensic patients, with a
comparable manifestation of side effects.
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TABLE 2
THE ANALYSIS OF ADMINISTERING MULTIPLE








N 22 34 56
% 22.45% 34.69% 57.14%
Atypical
N 24 18 42
% 24.49% 18.37% 42.86%
Total
N 46 52 98
% 46.94% 53.06% 100%
ODABIR ANTIPSIHOTIKA I AGRESIVNOST KOD SHIZOFRENIH PACIJENATA U USTANOVAMA
ZATVORENOG TIPA
S A @ E T A K
Odabir antipsihotika kao lijekova koji se primarno upotrebljavaju za lije~enje shizofrenije i shizofreniji sli~nih pore-
me}aja va`an je aspekt tretmana forenzi~nih bolesnika. Ovaj rad istra`uje utjecaj odabira vrste antipsihotika (tipi~nih
ili atipi~nih) na stupanj agresivnosti, izra`enost nuspojava i du`inu sada{nje hospitalizacije. Istra`ivanje je provedeno u
dvije forenzi~ne psihijatrijske ustanove na 98 psihijatrijskih bolesnika kod kojih je dijagnosticirana shizofrenija ili psi-
hoti~ni poreme}aj sli~an shizofreniji (F 20-F 29). Kazneno djelo po~inili su u stanju neubrojivosti i imalo je obilje`ja
agresivnog ~ina. Zbog sigurnosne mjere nalaze se na lije~enju u psihijatrijskoj ustanovi zatvorenog tipa. U istra`ivanju
je kori{ten upitnik za procjenu agresivnosti (AG-87), Simpson-Angus skala (SAS) za ispitivanje ekstrapiramidalnih
nuspojava, Barnesova skala (BARS) za procjenu akitazije i Upitnik nevoljnih abnormalnih pokreta (Abnormal involun-
tary movement scale (AIMS)). Rezultati pokazuju da nema zna~ajne razlike izme|u skupine na terapiji tipi~nim anti-
psihoticima i skupine na terapiji atipi~nim antipsihoticima na svim ispitivanim varijablama. S obzirom na preporu~ene
doze anipsihotika za forenzi~ne bolesnike ispitanici su hipodozirani.
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